Differential Effects of In Vitro Treatment with Cinobufotalin on Three Types of Ovarian Cancer Cells

Abstract

Background/Aim: Cinobufotalin (CINO), a cardiotonic steroid, has been used as an anticancer agent. This study assessed the cell-specific effect of CINO on SK- OV-3, CRL-1978 and CRL-11731 ovarian cancer cells which differ in terms of their respective karyotypes. Materials and Methods: Cell cultures were treated with CINO (0.1, 1, 5 and 10 μM) for 24, 48, and 72 h. Cell proliferation, migration, and invasion were measured using CellTiter, Cytoselect, and FluoroBlock assays, respectively. Expression of proliferating cell nuclear antigen (PCNA) was evaluated by western blot analysis. Cell viability was determined by fluorescence-activated cell sorting. Immunofluorescence was performed using Annexin-V staining and fluorescein isothiocyanate (FITC). Mitochondrial membrane potential (MMP) was measured using MitoTracker™ Red. Results: CINO at 0.5 μM inhibited SK- OV-3, CRL-1978, and CRL-11731 proliferation, migration, and invasion. Each cell type differed in response to CINO doses for PCNA, Annexin-V expression and MMP. Conclusion: The antineoplastic property of CINO is consistent, but its mode of action varies among cell lines.

Cinobufotalin regulates the USP36/c-Myc axis to suppress malignant phenotypes of colon cancer cells in vitro and in vivo

“…Due to its oncogenic function in colon cancer, the USP36/c-Myc axis may be a potential target for developing the anticancer drug. CBF, a cardiotonic steroid extracted from dried toad venom, exerts antitumor activity and has the ability to enhance the chemotherapeutic effect in several cancers [ 38 , 39 ]. However, whether CBF plays an anti-cancer function in colon cancer remains unknown.…”

The Potential Mechanisms of Cinobufotalin Treating Colon Adenocarcinoma by Network Pharmacology

“…Cinobufotalin was previously found to inhibit the activity of Na + /K + -ATP enzyme ( Akimova et al, 2005 ). In addition, cinobufotalin has inhibitory effects on many tumors, including lung, liver, ovarian, breast, and gastric cancers ( Kai et al, 2014 ; Cheng et al, 2015 ; Afroze et al, 2018 ; Li J. et al, 2019 ; Sun et al, 2019 ). More importantly, cinobufotalin also alters the sensitivity of chemotherapeutic drugs ( Li Y. et al, 2019 ; Liu et al, 2022 ).…”